How to Structure Psilocybin Dose Escalation for Bipolar II Depression
How should clinicians structure a cautious psilocybin dose-escalation pathway for adults with bipolar II depression?
Adults with bipolar II depression have often been excluded from psychedelic trials because of concern about mania risk, yet some remain severely depressed despite prior medication treatment. This study describes a practical specialty-setting pathway that starts with a lower psilocybin dose, embeds psychotherapy and safety monitoring, and only escalates if depression persists and the first session is tolerated.
-
Confirm that the patient matches the study population
Use this approach only for adults aged 18 to 70 years with bipolar II disorder who are in a current major depressive episode lasting more than 4 weeks and have at least moderate depressive severity, defined in the trial as MADRS greater than 18. Participants also had at least 1 prior unsuccessful medication trial for bipolar II disorder lasting at least 6 weeks.
-
Screen for exclusionary safety risks before treatment
Exclude patients with serious cardiovascular, neurological, or other medical illness, current hypomania, history of psychotic disorder, moderate or greater substance use disorder in the past 12 months, psychedelic use within 6 months, or baseline C-SSRS score of 4 or greater. The trial also used serum laboratory testing, electrocardiogram, physical examination, vital signs, detailed medical history, and SCID-5 interview before treatment.
-
Address interacting medications and social safety supports
When participants were taking medications with potential psilocybin interactions, the study tapered them so they were cleared for at least 5 half-lives before each administration. Each participant also designated a support person who saw them in person at least 5 days per week and helped monitor behavior and provide transport after sessions.
-
Pair the patient with psychotherapy before dosing
After eligibility and baseline assessment, each participant was paired with a licensed marriage and family therapist with master's-level training for psychotherapy before, during, and after psilocybin administration. Participants completing 1 session received more than 14 hours of psychotherapy, and those completing 2 sessions received more than 27 hours.
-
Begin with a 10 mg psilocybin session
All participants first received 10 mg of oral synthetic psilocybin in a standardized living-room-like setting. On the dosing day, vital signs and urine drug screen were used to confirm safety for administration, and the participant's therapist plus an assisting therapist provided continuous monitoring and psychological support during the acute effects.
-
Reassess at days 7, 14, and 21 after the first session
The study repeated structured assessments 7, 14, and 21 days after the 10 mg session. Depression severity was reassessed with MADRS, and safety monitoring included suicidality, mania, psychosis, insomnia, adverse events, and vital sign review as described in the protocol.
-
Escalate to 25 mg only if depression persists and 10 mg was tolerated
Patients became eligible for a second session only if the 10 mg dose was well tolerated and depressive symptoms persisted at day 21, defined by MADRS 7 or greater. This protocol was designed to avoid exposing patients who were no longer depressed to a higher 25 mg dose.
-
Hold the second dose if remission is reached after 10 mg
Do not proceed to 25 mg when the patient has already remitted by day 21 after the initial session, because the study protocol used symptom remission to stop escalation. In this trial, 4 of 14 participants met remission criteria of MADRS 6 or less after 10 mg and therefore did not receive 25 mg.
Clinical Considerations
- This was a small open-label pilot study, so the protocol should not be interpreted as a validated standard-of-care treatment pathway.
- The sample excluded bipolar I disorder, current hypomania, psychotic disorders, recent substance use disorder, and many concomitant psychotropic medications, limiting generalizability.
- The observed remissions after 10 mg may reflect therapeutic effect, placebo response, or both, and the authors state that more work is needed to evaluate the 10 mg dose.
- The article describes use in a highly supported research-like setting with psychotherapy, multiple assessments, and therapist monitoring during sessions.
Bottom Line
In this study, psilocybin-assisted therapy for bipolar II depression was structured as 10 mg first, then 25 mg only at day 21 if the first dose was tolerated and MADRS remained 7 or higher.
